First Financial Bankshares Inc Grows Stake in Amgen Inc. $AMGN

First Financial Bankshares Inc increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 220,422 shares of the medical research company’s stock after purchasing an additional 1,552 shares during the quarter. First Financial Bankshares Inc’s holdings in Amgen were worth $62,203,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its position in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 114 shares in the last quarter. Schnieders Capital Management LLC. grew its holdings in shares of Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after purchasing an additional 5,853 shares during the last quarter. MQS Management LLC acquired a new stake in shares of Amgen during the second quarter worth about $202,000. Finally, Oppenheimer Asset Management Inc. lifted its holdings in shares of Amgen by 23.9% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,098 shares of the medical research company’s stock valued at $307,000 after purchasing an additional 212 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Rothschild & Co Redburn raised their price target on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research note on Wednesday, February 18th. DZ Bank raised their target price on shares of Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. Piper Sandler lifted their target price on shares of Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Freedom Capital cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. Finally, Wells Fargo & Company raised their price objective on shares of Amgen from $325.00 to $375.00 and gave the stock an “equal weight” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $351.76.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $379.42 on Tuesday. The stock has a fifty day moving average price of $344.29 and a 200 day moving average price of $317.21. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $385.12. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The company has a market cap of $204.53 billion, a PE ratio of 26.66, a P/E/G ratio of 3.71 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the prior year, the firm earned $5.31 EPS. Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s dividend payout ratio is currently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.